ArticleEmerging topics in life sciences2019
Synthetic biology industry: data-driven design is creating new opportunities in biotechnology.
Article in Emerging topics in life sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Highly multiplexed mammalian metabolic engineering with a shotgun approach.Nature biotechnology · 2026Article
- Innovations and challenges in collagen and gelatin production through precision fermentation.World journal of microbiology & biotechnology · 2025Review
- Deconstructing synthetic biology across scales: a conceptual approach for training synthetic biologists.Nature communications · 2024Review
- Data hazards in synthetic biology.Synthetic biology (Oxford, England) · 2024Review
- The whack-a-mole governance challenge for AI-enabled synthetic biology: literature review and emerging frameworks.Frontiers in bioengineering and biotechnology · 2024Review
- Golden Standard: a complete standard, portable, and interoperative MoClo tool for model and non-model proteobacteria.Nucleic acids research · 2023Article
- Graph Visualization: Alternative Models Inspired by Bioinformatics.Sensors (Basel, Switzerland) · 2023Review
- Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene Therapies.ACS synthetic biology · 2023Review
- Unigems: plasmids and parts to facilitate teaching on assembly, gene expression control and logic inAccess microbiology · 2023Article
- Prediction of strain engineerings that amplify recombinant protein secretion through the machine learning approach MaLPHAS.Engineering biology · 2022Article
- Machine Learning Guided Batched Design of a Bacterial Ribosome Binding Site.ACS synthetic biology · 2022Article
- Data-Driven Synthetic Cell Factories Development for Industrial Biomanufacturing.Biodesign research · 2022Review
- Schrödinger and the Possible Existence of Different Types of Life.Frontiers in microbiology · 2022Article
- basicsynbio and the BASIC SEVA collection: software and vectors for an established DNA assembly method.Synthetic biology (Oxford, England) · 2022Article
- De novo synthesis of synthetic biology ecosystem in Slovakia: Challenges and opportunities.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- Principles of synthetic biology.Essays in biochemistry · 2021Article
- Intelligent host engineering for metabolic flux optimisation in biotechnology.The Biochemical journal · 2021Review
- Post-Transcriptional Control in the Regulation of Polyhydroxyalkanoates Synthesis.Life (Basel, Switzerland) · 2021Review
- Future trends in synthetic biology in Asia.Advanced genetics (Hoboken, N.J.) · 2021Article
- Enabling high-throughput biology with flexible open-source automation.Molecular systems biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic biology is a rapidly emerging interdisciplinary research field that is primarily built upon foundational advances in molecular biology combined with engineering design. The field considers living systems as programmable at the genetic level and has been defined by the development of new platform technologies. This has spurned a rapid growth in start-up companies and the new synthetic biology industry is growing rapidly, with start-up companies receiving ∼$6.1B investment since 2015 and a global synthetic biology market value estimated to be $14B by 2026. Many of the new start-ups can be grouped within a multi-layer 'technology stack'. The 'stack' comprises a number of technology layers which together can be applied to a diversity of new biotechnology applications like consumer biotechnology products and living therapies. The 'stack' also enables new commercial opportunities and value chains similar to the software design and manufacturing revolution of the 20th century. However, the synthetic biology industry is at a crucial point, as it now requires recognisable commercial successes in order for the industry to expand and scale, in terms of investment and companies. However, such expansion may directly challenge the ethos of synthetic biology, in terms of open technology sharing and democratisation, which could unintentionally lead to multi-national corporations and technology monopolies similar to the existing biotechnology/biopharma industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.